$IBRX News
Last published 1d ago
- 1d agoIBRXNew U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to CareBusiness WireCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced findings from a national survey of military service members and veterans with non-muscle invasive bladder cancer (NMIBC). The survey, conducted by The Harris Poll on behalf of ImmunityBio, found that 53% of respondents were diagnosed by age 50 and 63% reported barriers ...
- 1d agoIBRXImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026Business WireCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced members of the senior leadership team will speak at the upcoming Jefferies Global Healthcare Conference and the UBS Global Biopharma Conference, both held in London during Life Sciences Week 2026, November 15-20. “The results from our QUILT-2.005 study bring us closer t ...
- 3d agoIBRXImmunityBio, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 3d agoIBRXImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 MillionBusiness WireCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced continued global expansion, expanded FDA approval, and financial results for the third quarter ended September 30, 2026. ImmunityBio continued to advance a broad clinical pipeline spanning bladder cancer, non-small cell lung cancer, and hematologic malignancies with exp ...
- 3d agoIBRXImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in SituBusiness WireJERUSALEM & CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) (“ImmunityBio”) and Rafa Laboratories Ltd. (TASE: RAFA) (“Rafa”) today announced that the Israeli Ministry of Health (MoH) has granted approval for ANKTIVA® (nogapendekin alfa inbakicept), indicated in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscl ...
- 3d agoIBRXImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 TrialBusiness WireCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled, registrational trial evaluating intravesical ANKTIVA® (nogapendekin alfa inbakicept-pmln/N-803) in combination with Bacillus Calmette-Gué ...
- 3w agoIBRXImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder CancerBusiness WireDatabase lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle invasive bladder
- 3w agoIBRXImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary TumorsBusiness WirePeer-reviewed publication reports long-term outcomes from the QUILT-3.032 study supporting durable disease control and bladder preservation ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today
- 4w agoIBRXFDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS DiseaseBusiness WireExpanded indication extends ANKTIVA plus BCG to patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), including those with carcinoma in situ (CIS), with or without papillary tumors, and those with
- 1mo agoIBRXImmunityBio to Participate in the Piper Sandler Virtual Oncology SymposiumBusiness WireImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Global Chief Scientific and Medical Officer, will participate
- 1mo agoPDSBIBRXNHPDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of DirectorsGlobeNewswireGross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB)
- 3mo agoIBRXImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice ChairmanBusiness WireDr. Kim will advise on international partnerships and global access initiatives through the newly formed Office of the Executive Chairman ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today
- 3mo agoIBRXImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 MillionBusiness WireQ2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially from Q1 2026, marking the eighth consecutive quarter of sequential revenue growth since the commercial launch of ANKTIVA®,
- 3mo agoIBRXImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung CancerBusiness WireThe UAE authorization further expands ANKTIVA’s global regulatory footprint to 34 countries. The BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) authorization is the first worldwide to span the full
- 5mo agoFATEGTBPIBRXIOVA+1Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE BetGlobeNewswireIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while
- 5mo agoBNTXIBRXKZIANTHIThe Multi-Billion-Dollar Search for Better Glioblastoma TreatmentsGlobeNewswireDENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted
- 5mo agoIBRXImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026Business WirePresentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC) ImmunityBio, Inc. ((
- 5mo agoGTBPIBRXFATENKTX+1The $13 Million Company Teaching the Immune System to Hunt CancerPR NewswireUSA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)...
- 5mo agoIBRXThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRXPR NewswireThe Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during...
- 5mo agoIBRXImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.GlobeNewswireNEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ImmunityBio Inc. (NASDAQ:IBRX) ("ImmunityBio" or the "Company") for potential violations of the
- 5mo agoIBRXImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CISBusiness WireAnalysis demonstrates a lower cost per sustained responder and cystectomy avoided with ANKTIVA plus BCG compared to TAR-200 in Medicare population over three years ImmunityBio, Inc. ((
- 5mo agoIBRXImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder PreservationBusiness WireUK-based study identifies key patient-centered factors influencing treatment preferences in high-risk NMIBC ImmunityBio, Inc. ((
- 5mo agoIBRXImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027Business WireSupplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary disease FDA noted in its filing communication that the supplemental BLA accepted for review was based
- 5mo agoGTBPFATENKTXIBRX+1Three TriKE Candidates In Clinic As NK Cell Engager Field ReorganizesPR NewswireThe case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first ...
- 5mo agoIBRXImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026Business WireNAI+BCG versus Nadofaragene Results: NAI+BCG treated patients were twice as likely to achieve a complete response (CR) at any point of the study versus nadofaragene firadenovec-vncg in BCG-unresponsive non-muscle
- 5mo agoIBRXImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035Business WireFive issued U.S. patents cover the combination of ImmunityBio's IL-15 receptor agonist (NAI) with Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer treatment, with terms extending through at least
- 5mo agoIBRXImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United StatesBusiness WirePositive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tokyo strain of BCG (Tokyo-172 BCG) versus TICE BCG in BCG-naïve
- 6mo agoIBRXINKTMiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical ValidationGlobeNewswireRandomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026AACR and ASGCT presentations showcase durable survival and
- 6mo agoGTBPARTVFATEIBRX+1Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth PhasePR NewswireMomentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering encouraging results across...
- 6mo agoIBRXIBRX Lawsuit Alleges Company Allegedly Violated FDA Drug Rules - ImmunityBio Investors Face Losses Following Company Allegedly Violated FDA Drug Rules: SueWallStPR NewswireIMPORTANT DATE: May 26, 2026. Investors who wish to seek appointment as lead plaintiff in the ImmunityBio, Inc. (NASDAQ: IBRX) securities class...
- 6mo agoIBRXImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 MillionBusiness WireQ1 2026 Revenue Growth with Continued Strong Sales Momentum: $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 and up 15% from Q4 2025 ANKTIVA® Unit Growth: 168% increase in
- 6mo agoIBRXImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual MeetingBusiness WireCross-trial analyses comparing ANKTIVA + BCG with nadofaragene firadenovec-vncg and TAR-200 provide important context, particularly in the absence of head-to-head data, highlighting its efficacy, durability, and safety
- 6mo agoIBRXImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.GlobeNewswireNEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ImmunityBio Inc. (NASDAQ:IBRX) ("ImmunityBio" or the "Company") for potential violations of the
- 6mo agoIBRXImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA PartnershipBusiness WireANKTIVA approved for patients with certain indications of non-muscle invasive bladder cancer and non-small cell lung cancer Commercial availability achieved within two months of announcing MENA partnership with
- 7mo agoIBRXREMINDER: ImmunityBio, Inc. Investors With Significant Losses Must Act By May 26, 2026GlobeNewswireNEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ:IBRX) investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a
- 7mo agoIBRXImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.GlobeNewswireNEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ImmunityBio Inc. (NASDAQ:IBRX) ("ImmunityBio" or the "Company") for potential violations of the
- 7mo agoIBRXImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable SecuritiesBusiness WirePreliminary Q1 2026 net product revenue of approximately $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 Consistent quarter-over quarter revenue growth since commercial launch,
- 7mo agoIBRXIBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff RoleBusiness WireIf you have suffered a loss on your ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ:IBRX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the
- 7mo agoIBRXImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising ComplianceBusiness WireCompany initiated a comprehensive review of promotional materials and is implementing enhanced advertising compliance measures, including expanded promotional review protocols, executive training, and external
- 7mo agoIBRXImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy PipelineBusiness WireImmunityBio to receive $75 million in non-dilutive funding under existing Revenue Interest Purchase Agreement (RIPA) with Oberland Capital, bringing total committed capital to $375 million Simultaneously conversion
- 7mo agoIBRX$IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover LossesGlobeNewswireBOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Block & Leviton announces that a securities fraud lawsuit has been filed against ImmunityBio, Inc. (NASDAQ:IBRX) and certain of its executives. Investors who have lost
- 7mo agoIBRXFATEGUTSMBRXScalable Biotech Manufacturing Unlocks a $14B MarketPR NewswireUSANewsGroup.com News Commentary — The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to surpass $7...
- 7mo agoIBRXImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026Business WireThe QUILT-2.005 randomized clinical trial is on track for final analysis and supplemental Biologics License Application (BLA) submission in 2026 for the BCG-naïve NMIBC carcinoma in situ with or without papillary
- 7mo agoIBRXImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary TumorsBusiness WireMacau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive NMIBC with CIS ± papillary tumors Authorization follows a reliance-based review
- 8mo agoIBRXImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only DiseaseBusiness WireRecommendation is based on peer-reviewed clinical data supporting long-term effectiveness and safety durability in patients with papillary-only disease treated with ANKTIVA plus BCG1. ImmunityBio, Inc. ((
- 8mo agoIBRXImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer DonorsBusiness WireMethods developed and validated to establish the "World Bank of NK Cells" from healthy donors and cancer patients Single apheresis yields up to 5 billion (5×109) highly pure activated memory cytokine-enhanced NK
- 8mo agoIBRXImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional DataPR NewswireImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has...
- 8mo agoIBRXImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026Business WireImmunityBio, Inc. ((
- 8mo agoIBRXImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In SituBusiness WireStudy fully enrolled ahead of schedule, with 366 of 366 BCG-naïve NMIBC patients randomized to receive BCG alone or ANKTIVA plus BCG Interim analysis requested by the FDA demonstrated a statistically significant
- 8mo agoONCYIBRXCRSPBNTX+1Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026PR NewswireEquity Insider News Commentary, The immuno-oncology market is forecast to grow from $65.22 billion in 2025 to $170.19 billion by 2032, fueled by...